Molecular modeling of μ opioid receptor and receptor-ligand interaction¹

RONG Suo-Bao², ZHU You-Cheng, JIANG Hua-Liang, ZHAO Shan-Rong, WANG Qing-Mi, CHI Zhi-Qiang, CHEN Kai-Xian, JI Ru-Yun (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China)

KEY WORDS mu opioid receptors; molecular models; ligands; binding sites; fentanyl; structureactivity relationship

AIM: To construct the 3D structural model of μ opioid receptor (μOR) and study the interaction between μOR and fentanyl derivatives. METHODS: The 3D structure of μ OR was modeled using the bacteriorhodopsin (bRh) as a template, in which the alignments of transmembrane (TM) of bRh and μ OR were achieved by scoring the alignment between the amino acid sequence of μOR and the structure of bRh. The fentanyl derivatives were docked into the 7 helices of μ OR and the binding energies were calculated. RESULTS: (1) The receptor-ligand interaction models were obtained for fentanyl derivatives. (2) In these models, the fundamental binding sites were possibly Asp147 and His297. The negatively charged oxygen of Asp147 and the positively charged ammonium group of ligand formed the potent electrostatic and hydrogen-binding interactions. Whereas the interactions between the positively charged nitrogen of His297 and the carbonyl oxygen of ligand were weak. In addition, there were some $\pi = \pi$ interactions between the receptor and the ligand. (3) The binding energies of the receptorligand complexes had a good correlation with the analgesic activities $(- \lg ED_{50})$ of the fentanyl derivatives. CONCLUSION: This model is helpful for understanding the receptor-ligand interaction and for designing novel #OR selective ligands.

Fentanyl was a potent $analgesic^{(1)}$. Its prominent bioactivity and characteristic structure attracted a great attention. Four enantiomers of 3-

.

Received 1996-04-29 Accepted 1997-03-05

methylfentanyl (Met) and 8 enantiomers of ohmefentanyl (Ohm) were synthesized in our laboratory^(2,3). There were tremendous stereodifferences between their analgesic activities and affinities for μ opioid receptor (μ OR). Like many other fentanyl derivatives, they were selective μ OR agonists⁽⁴⁾.

The amino acid sequence of μOR from rat and determined from human was its **cDNA** sequence^[5,6]. The rat μ OR consisted of 398 amino acid residues and the N-terminal was in the extracellular space, the C-terminal in the cytoplasm.

In this paper, the three-dimensional (3D) structural model of μ OR was constructed using the structure of bacteriorhodopsin (bRh) as a template. Then, the receptor-ligand interaction of fentanyl analogs was investigated by studying the bioactive conformations of ligands in the receptor and the relationship between the binding energies and the bioactivities of the ligands.

METHODS

Primary sequence comparison between μ OR and bRh as well as hydropathicity analysis were made to define the putative transmembrane (TM) regions. The 7 TM domains were transformed into α -helices with the normal φ and Ψ values of -58° and -47° , respectively, except for proline residue with $\varphi - 75^{\circ}$, which led to slightly bent α -helices. The refined model of bRh, which was obtained from the Protein Data Bank (entry 1BRD)⁽⁷⁾, was used as the template for positioning the 7 α -helices of μ OR.

Modeling was achieved with the molecular modeling package SYBYL $6.2^{(8)}$. The interactive modeling and display were performed on SGI XZ 4000 workstation. The receptor was optimized in SYBYL using molecular mechanics calculation with the following parameters: a distancedependent dielectric constant of 5.0, nonbonded cut-off 0.8 nm, AMBER force field with Kollman all-atom charges, conjugate gradient minimization until the RMS energy gradient $< 0.7 \text{ kcal} \cdot (\text{mol} \cdot \text{nm})^{-1}$. First, the all sidechains of 7 helices were minimized to convergence, in which the

¹ Project supported by the National Natural Science Foundation of China, No 39470805.

²Phn: 86-21-6431-1833. Fax: 86-21-6437-0269.

E-mail; rong@iris3.shmm.ac.cn

backbone of μOR was aggregated; then, the whole receptor was minimized to convergence.

The selective ligands for μ OR were manually docked into their putative binding sites in the 7 helix bundles. To get the best possible interaction complexes, the docking procedure was repeated several times, simultaneously regulating different initial orientations for both the receptor side chains and the ligand. The complexes were optimized by molecular mechanics calculations using Tripos force field with Kollman all-atom charges for the receptor and Gasteiger-Huckel charges for the ligands. In this study, the 19 selective μ OR ligands (shown below) were docked into the receptor model.



Morphine



	\mathbf{R}_1	R ₂	R ₃
Fentanyl	н	H	Н
3-Methylfentanyl	н	CH₃	H (4 isomers)
Obmefentany l	ЮН	CH ₃	H (8 isomers)
Carfentanil	H	H	COOCH ₃
Lofentanil	H	CH ₃	COOCH ₃ (4 isomers)

RESULTS AND DISCUSSION

Modeling of μ OR In 1990, a high quality 3D model for bRh was determined based on cryomicroscopy experiments⁽⁷⁾. The bRh receptor lacked sequence homology with G protein-couple receptor (GPCR), but it paralleled with GPCR in overall 3D structure patterns. The bRh had the similar functional characteristics and the structural

patterns to rhodopsin^[12], which had sequence homology with GPCR. It seems very likely that bRh and rhodopsin as well as other GPCR belong to the same structural class. It was reasonable that the 3D structure of μ OR was modeled using the bRh structure as a template.

According to the method of scoring sequencestructure alignments⁽⁹⁾, the plots of scores as a function of threading shift were obtained when threading the sequence of μ OR through the bRh structure (Fig 1).



Selected alignments of TM1 (\bigcirc), TM2 (\bigcirc , TM3 (\checkmark), and TM4 (\Box) were the threading shifts of -1, 2, -1, and 0, respectively



Fig 1. Scoring alignments of μOR sequence and bRh structure.

Theoretically, the alignment with the highest score should be selected. On account of the complication of sequence alignment, the several alignments with higher score were tried to model μ OR. The sequence alignments of the TM of bRh and μ OR were chosen (Fig 2).

After energy minimization, the 3D model of μ OR was achieved. In this model, the face directed toward the lipid bilayer mainly consisted of the nonaromatic hydrophobic residues, whereas the inside of the 7 helix bundles mainly of the conserved, polar residues. This arrangement was in accordance with the helical conformation of GPCR⁽¹⁰⁾.

Due to the conformational flexibility of extraand intra-cellular loop regions, the loop regions connecting individual helices were omitted in the present modeling. However, omission of the loop regions was not influential in analyzing the receptorligand interaction, because the ligand-binding pocket was supposed to be located in the region surrounded by transmembrane helices^(7,10).

тмі	ծRh	11	IWLALGTALMGLGTLYFLV KOM	32
	µO R	71	IMALYS I VCVVGLFGNFLVMYV	92
TM2	bRh	3 8	DAKKEYA I TTLVPAIAETMYL SML	61
	µOR	107	I E NLALADALATS TLPEQSVNYLM	130
тмз	bRh	81	ARYADWLF T TPLLLEDL ALL	100
	μOR	142	IV 1 S 1 DYYNMFTSI FT LCTM	161
TM4	ծRh	108	ILA LVGADGI MI GTGLVGAL	127
	µOR	186	IVNVCNWI LS SA IG LPVMFM	205
TM5	bRh	137	WWAI STAAMLYILYVLFFGFT	157
	µOR	234	I C VF IFA FI MPIL I ITVCYGL	254
TM6	ծRh	167	VAS TEKVLR NVT VVEWSAYPV	187
	µOR	282	VLVVVAVE I VCWTP I H I VVI I	302
ТМ7	bRh	204	ETLLFMVLDVSAKVG FGLI	222
	µGR	321	CIALGY TNSCLNPV LYAFL	330

Fig 2. Sequence alignment of transmembrane regions of bRh and μOR .

Modeling of ligand-receptor complexes The 13 protonated ligands (including fentanyl, 4 enantiomers of Met, and 8 enantiomers of Ohm) were docked into the inside of 7 helix bundles. In

Tab 1. Geometric parameters of binding sites of µOR model.

docking procedure, the bioactive conformations of the ligands were chosen as our previous results⁽¹¹⁾.

We found 3 charged residues in TM region, ie, 2 negatively charged residues (Asp114 and Asp147) and 1 positively charged residue (His297). Of these amino acid residues, 2 Asp residues were conserved with all GPCR^[13]. The site-directed mutagenesis showed that Asp147 residue played an important role in binding with agonist.

Our previous study⁽¹¹⁾ showed that, the distance between RP₁ and RP₂ was about 0.93 nm, corresponding to the distance between the 2 hypothetical site points binding with the protonated nitrogen of piperidine and the carbonyl oxygen of 4-phenylpropanamide of ligand, respectively. It was in accordance with the distance between the negatively charged oxygen of Asp147 and the positively charged nitrogen of His297 in our μ OR model (Tab 1).

Therefore, the residues Asp147 and His297 would be chosen as the binding sites, which were consistent with the results of modeling receptorlofentanil interaction^[14].

After manual adjustment, the docking procedure was carried out to convergence. For each ligand-receptor complex, the geometric optimization was also performed to convergence. The 3D models of receptor-ligand complexes were obtained, one of

Compounds	d 1 "	ď۱۶	d2"	d_2^{b}	d₃ª	$d_{3}{}^{b}$	d₄ª	$d_4{}^b$
Fentanyl	0.569	0.582	0.797	0.923	0.695	0.718	1.060	1.026
(3R,4R)-Met	0.583	0. <i>5</i> 98	0.825	0.975	0.735	0.717	1.073	1.043
(3R,4S)-Met	0.583	0.583	0.803	0.937	0.716	0.715	1.089	1.078
(3S,4R)-Met	0.577	0.585	0.809	0.877	0.717	0.715	1.073	1.067
(3S,4R)-Mei	0.521	0.585	0.799	0.963	0.706	0.717	1.040	1.014
(3R,4R,2'R)-Ohm	0.610	0.695	0.834	0.940	0.736	0.717	0.070	1.066
(3R,4R,2'R)-Ohm	0.610	0.694	0.822	0.918	0.727	0.715	1.086	1.108
(3R,4R,2'R)-Ohm	0.576	0.568	0.827	0.874	0.723	0.715	1.071	1.046
(3R,4R,2'R)-Ohm	0.582	0.578	0.825	0.970	0.709	0.718	1.043	1.022
(3R,4R,2'R)-Ohm	0.592	0.568	0.829	0.958	0.737	0.718	1.059	1.009
(3R,4R,2'R)-Ohm	0.611	0.666	0.820	0.803	0.725	0.715	1.081	1.074
(3R,4R,2'R)-Ohm	0.593	0.590	0.808	0.882	0.719	0.715	1.074	1.070
(3R,4R,2'R)-Ohm	0.558	0.578	0.786	0.958	0.707	0.718	1.054	1.006

"Calculated in this study; ^b obtained from Ref 11; $d_1(nm)$ is the distance between the phenyl center of phenylethyl of ligand and the positively charged oxygen of Asp147, $d_2(nm)$ the distance between the positively charged oxygen of Asp147 and the negatively charged nitrogen of His297, $d_3(nm)$ the distance between the negatively charged nitrogen of His297 and the phenyl center of 4-phenylpropanamide of ligand, $d_4(nm)$ the distance between two phenyl rings of ligand.

.

which was shown in Fig 3.



Fig 3. Stereoplots of the (3R, 4S, 2`S)-Ohm in the binding sites. Only 2 residues (Asp147 and His297) and the trace of α -carbon atoms of μ OR. (A) Top view of the cell; (B) Side view of the membrane.

According to the above models, the possible binding sites were mainly defined by the following amino acids: Asp147 (TM3), His297 (TM6), Tyr148 (TM3), Trp192 (TM4), and Tyr326 (TM7), which were corresponding to the 4 key moleties of μ pharmacophore (Fig 4).



Fig 4. Four key moleties of μ pharmacophore of fentanyl derivatives interacting with putative binding sites of μ OR, shown for (3R,4S,2'S)-Ohm.

There were a number of interactions between the ligands and the amino acid residues in the receptor-ligand complex model. The potent electrostatic and hydrogen-binding interactions occurred from the negatively charged oxygen of Asp147 of the receptor to the positively charged ammonium group on piperidine ring of ligand, whereas the weak electrostatic and hydrogen-binding interactions between the positively charged nitrogen of His297 and the carbonyl oxygen of 4phenylpropanamide of ligand. There took place some $\pi - \pi$ interactions of receptor with ligands; the 2 aryl rings of residues Tyr148 and Trp192 interacted with the phenyl ring in 4phenylpropanamide of ligand, which was inserted between 2 above aryl rings; whereas the aryl ring of Tyr326 with the phenyl ring in N-phenylethyl of ligand.

Binding energies of the receptor-ligand complexes The binding energy $(E_{binding})$ of each ligand with μ OR was calculated as the follows:

 $E_{\text{binding}} = E_{\text{complex}} - E_{\text{ligand}} - E_{\text{receptor}}$ (1)

where E_{ligand} is the conformational total energy of the ligand corresponding to the bioactive conformation, and E_{receptor} is the energy of the optimized receptor (Tab 2).

With Partial Least Squares (PLS) method, the regression equation between $-\lg ED_{50}$ and $E_{binding}$ was achieved:

 $-\lg ED_{50} = -3.101 - 0.080 \cdot (E_{binding})$ (2) ($r^2 = 0.761, F = 35.06, s = 0.617$)

Obviously, the binding energies of receptor-ligand complexes had a good correlation to the analgesic activities of ligands. The more negative the value of E_{bunding} , the more potent the bioactivity of ligand.

However, the interaction energies obtained could not be used to calculate exact affinities of ligand-receptor, because changes in entropy and solvation were not taken into account.

Elucidation of structure-activity relationship (SAR) of ligands The receptor-ligand complex model could be used to explain the known SAR for the fentanyl analogs as $below^{(15)}$.

(1) Introducing a methyl into the 3-position of piperidine ring to form the 3R, 4S-configuration of Met and Ohm enhanced their analgesic activities and

Compounds	E_{complex}	E _{receptor}	$E_{ m ligard}$	$E_{ m bandang}$	~ lg ED ₅₀
Fentanyl	- 598.784	- 491.908	19.902	- 126,778	6.78
(3R,4R)-Met	- 591 . 113		15.900	-115.105	6.42
(3R,4S)-Met	-585.272		41.215	-134.579	7.76
(3S,4R)-Met	- 579.604		24.584	- 112, 280	5.69
(38,4S)-Met	- 594.605		19.060	- 121.757	7.01
(3R,4R,2'R)-Ohm	- 591.524		17.005	- 116.671	6.71
(3R,4S,2'R)-Ohm	- 577.826		45.154	- 131 .072	7.90
(38,4R,2'R)-Ohm	- 574.625		23.365	-106.082	4.57
(3S,4S,2'R)-Ohm	- 591.333		18.059	-117.484	6.69
(3R,4R,2'S)-Ohm	- 598.959		23.175	-130.226	7.58
(3R,4S,2'S)-Ohm	- 591.252		57.501	- 156.845	8.54
(3S,4R,2'S)-Ohm	-578.490		21.637	- 108.219	4.57
(38,48,2'8)-Ohm	- 591.7 09		29.012	- 128.813	7.41
Morphine ^a	- 536.662		20.984	- 65.738	
Carfentanil ^a	-642.647		9.444	- 160.183	
(3R,4R)-Lofentanil ^e	-620.602		10.852	- 139.546	
(3R,4S)-Lofentanil®	- 630.989		14.176	- 153.257	
(3S,4R)-Lofentanil ^a	- 583.584		10.786	- 102.462	

12.737

Tab 2. Binding energies of receptor-ligand interaction (kcal·mol⁻¹) and $\sim \lg ED_{50}$ (mol·kg⁻¹) in hot plate test on mice.

^a Not including in the regression equation (2); due to the absence of comparable $-\lg ED_{50}$ data.

~607.110

affinities for μ OR.

(3S,4S)-Lofentanil®

From our model, the residues Ile144, Tyr148, and Leu200 could form one small hydrophobic pocket, which might be occupied only by one methyl group and resulted in increasing hydrophobic interaction with ligands. So, the 3R, 4Sconfiguration of Met and Ohm had extremely higher analgesic activities. Changing this methyl group into allyl or propyl, the activities distinctly decreased, because the group was too long to enter the small hydrophobic pocket.

Contrarily, converting the above configuration into the 3S, 4R-configuration of Met and Ohm, the activities dramatically decreased, because the methyl group in this configuration escaped from the small hydrophobic pocket and had the steric hindrance with Tyr148.

(2) Introducing a hydroxyl group into the 2'position of phenylethyl increased the analgesic activity of ligands, which could be explained by forming electrostatic and hydrogen-binding interactions between Ser329 and this 2'-hydroxyl group. This interaction is very obvious in receptor-(3R,4S,2'S)-Ohm complex (Fig 4).

(3) To lengthen or shorten the chain of phenylethyl substituent led to a sharp decrease in

analgesic activity. This trend was because the cavity within the 7 helix bundles of μ OR model could not accommodate too long ligands; otherwise, small ligands could not efficiently interact with the binding sites.

- 127.939

(4) Replacement of the phenyl group in phenylethyl by some other rings, eg, aromatic heterocyclic, planar cyclic and planar-like oxygencontaining cyclic rings, might ensure certain analgesic activity. But the phenyl group was still the best, because other ring structures weakened the $\pi - \pi$ interaction with Tyr326.

(5) To introduce a nucleophilic or eletrophilic group into the phenyl of 4-phenylpropanamide generally resulted in a sharp decrease of analgesic activity. This was due to a weakening of the $\pi - \pi$ interactions with Tyr148 and Trp192 and producing seriously steric hindrance with nearby amino acid residues.

To conclude, the μ OR model achieved in this study is meaningful for understanding the receptorligand interaction and probably helpful for designing novel μ OR selective ligands.

REFERENCES

1 Janssen PAJ. A review of the chemical features associated with

strong morphine-like activity Br J Auaesth 1962; 34: 260-8

- 2 Wang ZX, Zhu YC, Chen XJ, JI RY Stereorsonners of 3methylfentanyl: synthesis, absolute conformation and analgesic activity. Acta Pharm Sin 1993; 28: 905 – 10
- 3 Wang ZX, Zhu YC, Chen XJ, JI RY Enantromers of ohmefentanyl: synthesis and analgesic activity Chin Ser Bult 1994; 39: 1432-4
- Goldstein A, Maidu A. Multiple opioid receptors: ligand P selectivity profiles and binding site signatures 7, 1 7 3 2 2 Mol Pharmacol 1989; 36; 265 72.
- 5 Chen Y, Mestek A, Liu J, Hurley JA, Yu L Molecular clorung and functional expression of a μ -opioid receptor from rat brain. Mot Pharmacol 1993; **44**: 8 12
- 6 Wang TB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human μ opioid receptor cDNA and genetic clones, pharmacological characterization and chromesomal assignment FEBS Lett 1994; 338: 217 - 22.
- 7 Hunderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH – Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mot Biol 1990; 213: 899 - 929
- SYBYL [computer program], version h.2 St Louis (MO): Tripos Associates Inc, 1995.
- 9 Cronet P, Sander C, Vriend G Modeling of transmembrane seven helix bundles Protein Eng 1993; 6: 59 - 64
- 10 Trumpp-Kallniever S, Hollack J, Bruinvets A, Hibert M. Modeling of G-protein-coupled receptors: application to dopathine, adrenaline, serotorum, acetylcholine, and mammahan opsin receptors. J Med Chem 1992; 35, 3448 ~ 62.
- Rong SB, Zhu YC, Jiang HL, Wang QM, Zhao SR. Chen KX, et al Interaction models of 3-methylfentanyl derivatives with p opioid receptor. Acta Pharmeol Sin 1996; 18: 128 - 32.

Findlay J. Ekopoulos E.
 Three-dimensional modeling of G protein-finked receptors.
 Trends Pharmeol Sci 1990; 11: 492 - 9

13 Savarese TM, Fraser CM In 20170 mutagenesis and the search for structure-function relationship among G protein-couple

ŝ,

receptors Biochem J 1992; 283: 1 ~ (9

- Uht GR, Childers S, Pasternak G
 An opiate-receptor gene family reunion.
 Trends Neurosei 1994; 17: 89 ~ 93
- 15 Chi ZQ, Chen C, Wang CQ, Ge BL, Fang SN, Jin WQ, et al. Studies on the action of 3-methylfentanyl derivatives on the oprate receptor. In: Burns JJ, Tsuchitani PJ, editors. US-China Pharmaeology Symposium: Washington IC, 1980; 253 – 87.

ΈS,

μ 阿片受体及受体-配基相互作用的分子模拟

戎鎮宣,朱友成,蒋华良,赵善荣,王沁泌, 池志强,陈凯先,嵇汝运 R.7717 (中国科学院上海药物研究所,上海 200031、中国)

关键词 <u>µ阿片受体;分子模型;配基;</u> 结<u>合位点</u>;芬太尼;结构-活性关系

目的: 构建 μ 阿片受体(μ OR)的三维结构模型并 研究它与芬太尼衍生物的相互作用、 方法: 以细 菌视紫红质为模板, 模拟 μ OR 的三维结构; 然后, 将芬太尼衍生物对接到 μ OR 的七个 α 螺旋束之 内,并计算结合能. 结果: (1)得到受体 – 配基作 用模型. (2) 模型中,基本结合位点可能是 Asp147 和 His297. Asp147 与配基的正电性铵基 形成强的静电和氢键相互作用,这种作用在 His297 和配基的羰基 O 原子之间较弱. 受体、 配基间还存在某些 $\pi - \pi$ 相互作用. (3)受体-配 基结合能与芬太尼衍生物的镶痛活性间有良好的 相关性. 结论: 模型有助于理解受体-配基的相互 作用和设计新的阿片 μ 选择性配基、